Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020

BusinessWire_EN 
0 0 13.01.20
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
 

MedinCell’s portfolio of long-acting injectable products progresses well. All innovative products are based on its proprietary BEPO® technology combined with active ingredients already known and marketed.

MedinCell’s portfolio includes three products at clinical stage:

  • Interim analysis of the current phase 3 clinical trials of the lead asset (mdc-IRM, maintenance treatment of schizophrenia) is expected during the second half of 2020
  • The phase 2 clinical trials of a second asset (mdc-CWM, post-operative pain and inflammation management) are ongoing
  • The third asset (mdc-TJK, antipsychotic) is in phase 1

Several candidates for clinical development are at formulation or preclinical stage. In particular, results of the ongoing studies of four programs should make it possible to select their candidate formulations in 2020: mdc-GRT, organ transplant ; mdc-WWM, contraception ; mdc-NVA, pain ; mdc-KPT, pain / animal health.

To access the full press release here, please visit https://invest.medincell.com/#news

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005843/en/

Medincell S.a. Stock

€14.30
4.340%
A very strong showing by Medincell S.a. today, with an increase of €0.60 (4.340%) compared to yesterday's price.

Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!